Navigation Links
Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
Date:5/20/2009

Activity of Blinatumomab in NHL and ALL Highlighted at the 14th Congress of the European Hematology Association (EHA)

Adecatumumab Combination Data in Breast Cancer to Be Presented at the American Society of Clinical Oncology (ASCO) Meeting

BETHESDA, Md., May 20 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced an oral(1) and a poster presentation(2) of blinatumomab data at the 14th Congress of European Hematology Association (EHA) taking place from June 4-7, 2009, in Berlin, Germany. Interim data from the phase 2 clinical trial with blinatumomab in patients with acute lymphoblastic leukemia (ALL) were chosen for an oral presentation, while an update from the phase 1 trial with blinatumomab in patients with non-Hodgkin's lymphoma (NHL) will be presented in a poster and include additional data on the durability of responses last presented at the American Society of Hematology meeting in December 2008 and efficacy data from additional patients.

Micromet also announced a poster presentation(3) for adecatumumab at the 45th annual meeting of ASCO taking place from May 29 - June 2 in Orlando, Florida. The new data will include an update of the data presented at the European Society of Oncology (ESMO) meeting in October of 2008.

(1) Topp et al, (2009) Blinatumomab (anti-CD19 BiTE(R)) for targeted therapy of minimal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing phase II study. 14th Congress of EHA (2009), abstract number 482; oral presentation on June 6 in Hall 15.2 at 8:15 AM.

(2) Klinger, et al. (2009) Pharmacodynamic analyses of peripheral blood from relapsed B-NHL pat
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 Your cell phone ... modeling lithium-ion battery storage capacity. , New research ... theoretical model created at Lawrence Livermore National ... predicts how carbon components will perform as electrodes. ... the urgent need for higher-performance batteries. Several key ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
(Date:7/23/2014)... Emirates (UAE) (PRWEB) July 23, 2014 ... recently announced that its biobanking project, Provia ... Ph.D. to its growing Advisory Board. Scott Wolf ... pleased to have Dr. Vaught onboard with Provia’s ever-expanding ... and expertise that Provia’s management team brings to this ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4
... YORK, June 8, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0548785/Future-of-White-Biotechnology-in-China.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... referred to the third wave in biotechnology, ...
... 7, 2011 Vaxart, Inc., a San Francisco biotechnology company ... I clinical trial. This is the first clinical study evaluating ... The trial site is in the United States. ... is demonstrated with one vaccine, we can expect that later ...
... 7, 2011 Infrared Systems International (OTCBB: IFRS) is pleased ... pilot study of its NatuRx™ HIV/AIDS treatment and will push ... AquaLiv concluded a pilot study with two HIV/AIDS patients ... of the first reported AIDS victims on June 5th, 1981. ...
Cached Biology Technology:Reportlinker Adds Future of White Biotechnology in China 2Reportlinker Adds Future of White Biotechnology in China 3Reportlinker Adds Future of White Biotechnology in China 4Reportlinker Adds Future of White Biotechnology in China 5Vaxart Begins First Oral Vaccine Clinical Trial 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 3
(Date:7/24/2014)... brewery has its own microbial terroir, meaning the microbial ... found in the product, creating the final flavor according ... Applied and Environmental Microbiology . This is the ... a sake brewery. , Many sake makers inoculate ... A. Mills of the University of California, Davis, but ...
(Date:7/24/2014)... cleanup experts gathered at NJIT this week for an ... the U.S. Environmental Protection Agency (EPA) to dredge toxic ... River. , The EPA has called the plan, which ... and capping sections of the riverbed, one of the ... would be dredged and disposed off-site. , "We need ...
(Date:7/24/2014)... research into the potato genes that best adapt to ... in rainfall and increased extremes of hot and cold ... in order to create new potato varieties that will ... seeking to find out how the current potato varieties ... higher and lower temperatures. , This research is part ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Neiker-Tecnalia is researching the potato genes that best adapt to climate change 2
... Mich.---By mimicking the structure of the silk moth,s antenna, ... better nanopore---a tiny tunnel-shaped tool that could advance understanding ... A paper on the work is newly published ... headed by Michael Mayer, an associate professor in the ...
... developed by researchers in Temple University,s College of Science ... cancer. The leptin receptor antagonist peptide, developed by ... attractive option for triple negative breast cancer treatment, especially ... their findings online in the European Journal of ...
... environmental researchers from across North America have been ... Based at Stanford University,s Woods Institute for the ... 1998 to help academic scientists make their knowledge ... program selects up to 20 mid-career academic environmental ...
Cached Biology News:Silk moth's antenna inspires new nanotech tool with applications in Alzheimer's research 2New peptide could be effective treatment for triple negative breast cancer 220 researchers selected as 2011 Leopold Leadership Fellows 220 researchers selected as 2011 Leopold Leadership Fellows 320 researchers selected as 2011 Leopold Leadership Fellows 4
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... electronic from BRAND adds ergonomics and ... the only electronic, motor-driven repeating pipette ... including BRAND PD-Tip syringe tips, Eppendorf ... Tips,and VWRbrand Combi-Syringes. Select virtually any ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Biology Products: